Beclomethasone - Revision history

Rossdonaldson1: /* References */

2020-04-05T19:31:12Z

References

← Older revision		Revision as of 19:31, 5 April 2020
Line 54:		Line 54:

	<references/>		<references/>
	[[Category:Pharmacology]] [[Category:~~Pulmonology~~]]		[[Category:Pharmacology]] [[Category:Pulmonary]]

ClaireLewis at 21:29, 19 September 2019

2019-09-19T21:29:57Z

← Older revision		Revision as of 21:29, 19 September 2019
Line 54:		Line 54:

	<references/>		<references/>
	[[Category:Pharmacology]]		[[Category:Pharmacology]] [[Category:Pulmonology]]

Fletc151: /* References */

2019-06-10T13:16:30Z

References

← Older revision		Revision as of 13:16, 10 June 2019
Line 44:		Line 44:

	==References==		==References==
			*ACOG Committee on Practice Bulletins-Obstetrics, "ACOG Practice Bulletin: Clinical Management Guidelines for Obstetrician-Gynecologists Number 90, February 2008: Asthma in Pregnancy," Obstet Gynecol, 2008, 111(2 Pt 1):457-64. [PubMed 18238988]
			*Bakhireva LN, Jones KL, Schatz M, et al, “Asthma Medication Use in Pregnancy and Fetal Growth,” J Allergy Clin Immunol, 2005, 116(3):503-9. [PubMed 16159616]
			*Fanta CH. Acute exacerbations of asthma in adults: Home and office management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed February 7, 2019.
			*Global Initiative for Asthma (GINA). GINA report, Global Strategy for Asthma Management and Prevention. http://www.ginasthma.org. Updated 2018. Accessed October 23, 2018.
			*Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: 2014 Report. Global Initiative for Chronic Obstructive Lung Disease website. Published 2014.
			*Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: 2018 Report. Global Initiative for Chronic Obstructive Lung Disease website. http://goldcopd.org/wp-content/uploads/2017/11/GOLD-2018-v6.0-FINAL-revised-20-Nov_WMS.pdf. Published 2018. Accessed January 12, 2018.
			*Goedert JJ, Vitale F, Lauria C, et al, “Risk Factors for Classical Kaposi's Sarcoma,” J Natl Cancer Inst, 2002, 94(22):1712-8. [PubMed 12441327]
			*Lougheed MD, Lemière C, Dell SD, et al, “Canadian Thoracic Society Asthma Management Continuum - 2010 Consensus Summary for Children Six Years of Age and Over, and Adults,” Can Respir J, 2010, 17(1):15-24. [PubMed 20186367]

	<references/>		<references/>
	[[Category:Pharmacology]]		[[Category:Pharmacology]]

Humanguy: edited dosage forms, strengths, trade names

2017-10-11T22:41:08Z

edited dosage forms, strengths, trade names

← Older revision		Revision as of 22:41, 11 October 2017
Line 1:		Line 1:
	==Administration==		==Administration==
	*Type: [[Inhaled steroids]], [[Corticosteroid]]		*Type: [[Inhaled steroids]], [[Corticosteroid]]
	*Dosage Forms:		*Dosage Forms: oral inhalation aerosol, metered-dose nasal spray suspension, metered-dose nasal spray solution
			*Dosage Strengths: oral inhalation aerosol: 40, 80mcg/actuation; metered-dose suspension: 42mcg/actuation; metered-dose solution: 80mcg/actuation
	*Routes of Administration: inhalation, intranasal spray		*Routes of Administration: inhalation, intranasal spray
	*Common Trade Names: Qvar		*Common Trade Names: Qvar, Qvar RediHaler, Beconase AQ, QNASL

	==Adult Dosing==		==Adult Dosing==

ClaireLewis: /* Administration */

2016-10-05T07:44:30Z

Administration

← Older revision		Revision as of 07:44, 5 October 2016
Line 1:		Line 1:
	==Administration==		==Administration==
	*Type: [[Corticosteroid]]		*Type: [[Inhaled steroids]], [[Corticosteroid]]
	*Dosage Forms:		*Dosage Forms:
	*Routes of Administration: inhalation, intranasal spray		*Routes of Administration: inhalation, intranasal spray

ClaireLewis: /* See Also */

2016-10-05T07:41:51Z

ClaireLewis: Created page with "==Administration== Type: Corticosteroid Dosage Forms: Routes of Administration: inhalation, intranasal spray Common Trade Names: Qvar ==Adult Dosing== *Asthma: 40 to..."

2016-10-05T07:41:28Z

Created page with "==Administration== *Type: Corticosteroid *Dosage Forms: *Routes of Administration: inhalation, intranasal spray *Common Trade Names: Qvar ==Adult Dosing== *Asthma: 40 to..."

New page

==Administration==
*Type: [[Corticosteroid]]
*Dosage Forms:
*Routes of Administration: inhalation, intranasal spray
*Common Trade Names: Qvar

==Adult Dosing==
*Asthma: 40 to 320 mcg by oral inhalation BID
*Rhinitis: 2 sprays (80 mcg/spray) in each nostril once daily
==Pediatric Dosing==
*Asthma, 6-11 yo: 40-80 mcg by oral inhalation BID
*Rhinitis, 4-11 yo: 1 spray (40 mcg/spray) in each nostril once daily
==Special Populations==
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: C
*[[Lactation risk categories|Lactation risk]]: Infant risk minimal
*Renal dosing: no adjustment
*Hepatic dosing: no adjustment
==Contraindications==
*Allergy to class/drug
*Not to be used as primary treatment for acute asthma exacerbation

==Adverse Reactions==
===Serious===
*Secondary hypocortisolism
*Cataract, glaucoma
*Bronchospasm
===Common===
*Headache

==Pharmacology==
*Half-life: 0.3-3h
*Metabolism: Hepatic via CYP3A4
*Excretion: Mostly fecal

==Mechanism of Action==
*Corticosteroid, reduces inflammation

==Comments==

==See Also==
*
==References==
<references/>
[[Category:Pharmacology]]

← Older revision		Revision as of 07:41, 5 October 2016
Line 39:		Line 39:

	==See Also==		==See Also==
	*		*[[Corticosteroids]]
			*[[Asthma]]

	==References==		==References==
	<references/>		<references/>
	[[Category:Pharmacology]]		[[Category:Pharmacology]]